Announces Positive Clinical Results

Announces Positive Clinical Results

AVIV, Israel, October 15th, 2018 -- Cellect Biotechnology Ltd. (Nasdaq:

APOP), a developer of a novel

stem cell production technology, announced today further data from a Phase I/II study of its ApoGraft technology. With

half of the patients planned for the study having finished first month follow up, all such patients have shown 100% engraftment

with no procedure related adverse events reported. Further to the six patients' one month data detailed above, Cellect reports

that the first three patients of the trial (cohort I) have completed the study period (180 days) with full safety and tolerability.

to 50% of stem cell transplantation procedures result in life-threatening rejection disease and other immune responses such as

Graft-versus-Host-Disease (GvHD). These adverse reactions stem from the inability of current practice to select between cells

needed for successful transplant and those which cause the adverse effects. Cellect's ApoGraft technology aims to turn

stem cell transplantations into a simple and safe yet cost-effective procedure by proper selection of the needed cells and elimination

of the toxicity causing cells thereby reducing the associated severe side effects and consequently the outcome of the patients.

Phase I/II, dose escalating, 4-cohort, open label clinical trial of twelve patients is designed to evaluate the safety and

tolerability of the ApoGraft process in patients with hematological malignancies in an allogeneic hematopoietic stem cell

transplantation (HSCT). The primary endpoint of the study is overall incidence, frequency and severity of adverse events potentially

related to ApoGraft at 180 days from transplantation.

independent Data Safety Monitoring Board (DSMB) has reviewed the study results and approved dose escalation to 50 ng/ml FasL.

The first cohort in the study was dosed with 10 ng/ml FasL and the second was dosed with 25 ng/ml FasL. Based on the DSMB's

Cellect is proceeding with enrolling and dosing the third cohort of the study.

data is very encouraging and points to the potential of ApoGraft to make stem cell usage safe and effective. Eliminating

the cells that cause the adverse events in Bone Marrow Transplants validates the ability of the Apograft's selection process.

This proof of concept combined with the effect in Fat derived Stem cells further supports the generic use of Cellect's technology

from a variety of cell sources and widens the scope of applications within Regenerative Medicine", stated Cellect CEO Dr.

simple process selects and eliminates immune reaction-causing cells from the donor sample and delivers an improved cell batch

comprising enriched stem cells. The ApoGraft is intended to result in recovery of the patient's new immune system with

reduced related safety concerns in contrast to the significant morbidity or even death that happens a lot in currently standard

Cellect Biotechnology Ltd.

Biotechnology (NASDAQ: APOP)

has developed a breakthrough technology for the selection of stem cells from any given tissue that aims to improve a variety of

stem cell-based therapies.

Company's technology is expected to provide research, hospitals and pharma companies with the tools to rapidly isolate stem cells

in quantity and quality allowing stem cell-based treatments and procedures in a wide variety of applications in regenerative medicine.

The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment.

press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements

can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan",

"may", "should", "could", "might", "seek", "target", "will",

"project", "forecast", "continue" or "anticipate" or their negatives or variations of

these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example,

forward-looking statements are used in this press release when we discuss future potential results of the clinical trial. These

forward-looking statements and their implications are based on the current expectations of the management of the Company only

and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described

in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies

do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be

interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results

to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional

capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability

to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Company's ability

to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's

technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients

in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects;

the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection

the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without

infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen

scientific difficulties may develop with the Company's technology; and the Company's ability to retain or attract key employees

whose knowledge is essential to the development of its products. Any forward-looking statement in this press release speaks only

as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement,

whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities

laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk

Factors" in the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2017 filed with the U.S. Securities

and Exchange Commission ("SEC"), which is available on the SEC's website, http://www.sec.gov, and in the Company's

periodic filings with the SEC.

Eyal Leibovitz, Chief Financial Officer